These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1287 related items for PubMed ID: 25675380

  • 1. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.
    Li M, Yang M, Zhou X, Fang X, Hu W, Zhu W, Wang C, Liu D, Li S, Liu H, Yang G, Li L.
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1485-93. PubMed ID: 25675380
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Free androgen index and Irisin in polycystic ovary syndrome.
    Li H, Xu X, Wang X, Liao X, Li L, Yang G, Gao L.
    J Endocrinol Invest; 2016 May; 39(5):549-56. PubMed ID: 26584566
    [Abstract] [Full Text] [Related]

  • 5. Serum irisin and its regulation by hyperinsulinemia in women with polycystic ovary syndrome.
    Adamska A, Karczewska-Kupczewska M, Lebkowska A, Milewski R, Górska M, Otziomek E, Nikolajuk A, Wolczynski S, Kowalska I.
    Endocr J; 2016 Dec 30; 63(12):1107-1112. PubMed ID: 27616010
    [Abstract] [Full Text] [Related]

  • 6. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.
    Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, Kennedy CR, Lehnert H, Randeva HS.
    Diabetes; 2008 Jun 30; 57(6):1501-7. PubMed ID: 18375437
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
    Esfahanian F, Zamani MM, Heshmat R, Moini nia F.
    J Obstet Gynaecol Res; 2013 Apr 30; 39(4):806-13. PubMed ID: 23279603
    [Abstract] [Full Text] [Related]

  • 9. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
    Tziomalos K, Katsikis I, Papadakis E, Kandaraki EA, Macut D, Panidis D.
    Hum Reprod; 2013 Mar 30; 28(3):785-93. PubMed ID: 23315058
    [Abstract] [Full Text] [Related]

  • 10. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF, Nilas L, Madsbad S, Holst JJ.
    Metabolism; 2009 May 30; 58(5):586-93. PubMed ID: 19375579
    [Abstract] [Full Text] [Related]

  • 11. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
    Ciaraldi TP, Aroda V, Mudaliar SR, Henry RR.
    Metabolism; 2013 Nov 30; 62(11):1587-96. PubMed ID: 23958241
    [Abstract] [Full Text] [Related]

  • 12. An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet.
    Glueck CJ, Goldenberg N, Sieve L, Wang P.
    Metabolism; 2008 Jul 30; 57(7):954-60. PubMed ID: 18555837
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM.
    J Clin Endocrinol Metab; 2000 Aug 30; 85(8):2767-74. PubMed ID: 10946879
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans.
    Hu W, Li L, Yang M, Luo X, Ran W, Liu D, Xiong Z, Liu H, Yang G.
    J Clin Endocrinol Metab; 2013 Jan 30; 98(1):290-8. PubMed ID: 23185036
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
    Ozkaya M, Cakal E, Ustun Y, Engin-Ustun Y.
    Fertil Steril; 2010 Feb 30; 93(3):880-4. PubMed ID: 19111298
    [Abstract] [Full Text] [Related]

  • 19. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
    Romualdi D, De Marinis L, Campagna G, Proto C, Lanzone A, Guido M.
    Clin Endocrinol (Oxf); 2008 Oct 30; 69(4):562-7. PubMed ID: 18248643
    [Abstract] [Full Text] [Related]

  • 20. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS.
    J Clin Endocrinol Metab; 2000 Sep 30; 85(9):3161-8. PubMed ID: 10999803
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.